Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program ...
Personalis Inc. PSNL received a favorable reimbursement decision that could make its cancer test available to more patients — ...
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...
Utilization management criteria influence patients’ access to specialty drugs, yet the processes used by health plans to establish these criteria are not well understood. This study examined the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results